Abstract
Pemphigus vulgaris (PV) is a life-threatening autoimmune muco-cutaneous disease with formidable treatment challenges. Following the first report of successful treatment of PV in 1969 with azathioprine (AZA),1 which was originally used to treat cancers, and prevent rejection in organ transplantation recipients, AZA has been often used concomitantly with steroids in the treatment of PV. Although generally well tolerated by most patients, AZA can induce severe myelosuppression, especially leucopenia, in some susceptible individuals, thus resulting in serious microbial infections.
This article is protected by copyright. All rights reserved.
http://ift.tt/2ulplcA
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου